Arvinas presented preclinical data for ARV-393, a PROTAC BCL6 degrader, in combination with glofitamab at the 67th American Society of Hematology Annual Meeting.
The data support the initiation of a combination cohort in an ongoing Phase 1 clinical trial for diffuse large B-cell lymphoma.
The combination demonstrated significantly enhanced tumor growth inhibition and increased rates of tumor regression.
Enhanced Antitumor Activity
The combination of ARV-393 and glofitamab resulted in 81% tumor growth inhibition in a humanized high-grade B-cell lymphoma model.
Mechanistic Synergies
The combination showed synergies between BCL6 degradation with ARV-393 and T-cell engagement, enhancing antitumor activity.
Clinical Trial Initiation
The Phase 1 combination clinical trial for ARV-393 plus glofitamab is expected to start in 2026 for diffuse large B-cell lymphoma.
- The preclinical data indicate a promising potential for ARV-393 in the treatment of diffuse large B-cell lymphoma.
- This approach offers a chemotherapy-free treatment option addressing an unmet need for patients with limited therapeutic choices.
The preclinical data showcase the synergistic effects of ARV-393 and glofitamab, paving the way for a new chemotherapy-free treatment strategy in diffuse large B-cell lymphoma.